As a class of representative drugs targeting apoptosis, the most fundamental process of cell survival, BCL-2 inhibitors have exhibited attractive characteristics in treating cancers with robust on-target efficacy, standing out in the era of novel drugs. This evidence concerns the gene BCL2 and cancer.